nd
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Teriflunomide
Dihydroorotate dehydrogenase inhibitor
What it measured
Main measures
To evaluate the correlation between hange of the subpopulations of effector pro-inflammatory and anti-inflammatory T cells (% Th1 +% TC1 +% Th17 +% Tc17-% Th2) characterized by flow cytometry analysis, at baseline and during the early stages of treatment with teriflunomide to clinical and radiological response in one year of therapy.
Other measures (1)
To Assess the change from baseline in the subgroup of effector pro-inflammatory and anti-inflammatory T cells (% Th1 +% TC1 +% Th17 +% Tc17-% Th2) analyzed by flow cytometry, during treatment with teriflunomide to characterize which phenotype of immune response is primarily involved in the mechanism of action of the drug.
Immune response
Who could take part
Relapsing MS
Inclusion: Patients of male or female aged> 18 years, with relapsing remitting multiple sclerosis diagnosed according to the McDonald criteria 2010. Only patients candidates to treatment with teriflunomide will be enrolled Exclusion: <18 years of age; > 55 years of age.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The immunological profile of patients with multiple sclerosis is defined by the mutual balance of subpopulations of effector T cells, expressed as a sum of subpopulations of effector pro-inflammatory T cells and anti-inflammatory T cells (% Th1 +% TC1 +% Th17 +% Tc17-% Th2) .
Loading reviews and guidelines…
Related trials
History
Started
Feb 2018
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error